[go: up one dir, main page]

WO2007109102A3 - procedes d'intervention et de test d'agents mimetiques de restriction calorique (RC) - Google Patents

procedes d'intervention et de test d'agents mimetiques de restriction calorique (RC) Download PDF

Info

Publication number
WO2007109102A3
WO2007109102A3 PCT/US2007/006564 US2007006564W WO2007109102A3 WO 2007109102 A3 WO2007109102 A3 WO 2007109102A3 US 2007006564 W US2007006564 W US 2007006564W WO 2007109102 A3 WO2007109102 A3 WO 2007109102A3
Authority
WO
WIPO (PCT)
Prior art keywords
measuring
mimetic
methods
administering
testing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/006564
Other languages
English (en)
Other versions
WO2007109102A2 (fr
Inventor
Xi Zhao-Wilson
Paul C Watkins
Joseph M Dhahbi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarker Pharmaceuticals Inc
Original Assignee
Biomarker Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/378,032 external-priority patent/US8403844B2/en
Priority claimed from US11/377,986 external-priority patent/US7960605B2/en
Application filed by Biomarker Pharmaceuticals Inc filed Critical Biomarker Pharmaceuticals Inc
Publication of WO2007109102A2 publication Critical patent/WO2007109102A2/fr
Publication of WO2007109102A3 publication Critical patent/WO2007109102A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5085—Supracellular entities, e.g. tissue, organisms of invertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/02—Nutritional disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention a pour objet des procédés et des systèmes de surveillance d'interventions et/ou d'un sujet tel qu'un patient humain. L'un des modes de réalisation exemplaires d'un procédé comprend la mesure d'au moins un paramètre biologique d'un sujet, la détermination d'un état biologique à partir de la mesure, la réalisation (après la mesure) d'une intervention comportant l'administration au sujet d'un agent mimétique de restriction calorique (RC), la mesure, après l'administration, du paramètre biologique et la détermination d'un état biologique ultérieur à partir de la mesure post-intervention. L'invention concerne également des procédés de traitement de maladies neurologiques et de test d'agents mimétiques de restriction calorique (RC) et d'agents candidats au mimétisme de RC. Selon un mode de réalisation exemplaire, un agent candidat au mimétisme de RC est administré à un animal transgénique et les effets de cette administration sont ensuite déterminés, l'animal transgénique possédant un gène ajouté d'une autre race d'animal ou un gène modifié conçu pour produire une maladie ou un trouble de l'autre race d'animal et le procédé cherchant à déterminer si l'agent candidat au mimétisme de RC apporte ou non une amélioration dans la maladie ou le trouble. L'invention concerne également des procédés relatifs aux maladies neurologiques et d'autres procédés relatifs au test d'agents mimétiques de RC.
PCT/US2007/006564 2006-03-16 2007-03-15 procedes d'intervention et de test d'agents mimetiques de restriction calorique (RC) Ceased WO2007109102A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/378,032 2006-03-16
US11/378,032 US8403844B2 (en) 2006-03-16 2006-03-16 Methods for interventions
US11/377,986 US7960605B2 (en) 2006-03-17 2006-03-17 Methods for testing for caloric restriction (CR) mimetics
US11/377,986 2006-03-17

Publications (2)

Publication Number Publication Date
WO2007109102A2 WO2007109102A2 (fr) 2007-09-27
WO2007109102A3 true WO2007109102A3 (fr) 2007-12-06

Family

ID=38198114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/006564 Ceased WO2007109102A2 (fr) 2006-03-16 2007-03-15 procedes d'intervention et de test d'agents mimetiques de restriction calorique (RC)

Country Status (1)

Country Link
WO (1) WO2007109102A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518071A (ja) * 2011-06-15 2014-07-28 エヌエスイー プロダクツ インコーポレイテッド カロリー制限およびカロリー制限模倣物の同定用マーカー

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003088814A2 (fr) * 2002-04-17 2003-10-30 The Cleveland Clinic Foundation Marqueur systemique pour controler des mecanismes anti-inflammatoires et antioxydants d'agents therapeutiques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003088814A2 (fr) * 2002-04-17 2003-10-30 The Cleveland Clinic Foundation Marqueur systemique pour controler des mecanismes anti-inflammatoires et antioxydants d'agents therapeutiques

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANISIMOV VLADIMIR N ET AL: "Effects of phentermine and phenformin on biomarkers of aging in rats.", GERONTOLOGY 2005 JAN-FEB, vol. 51, no. 1, January 2005 (2005-01-01), pages 19 - 28, XP008081009, ISSN: 0304-324X *
BAUER JOHANNES H ET AL: "An accelerated assay for the identification of lifespan-extending interventions in Drosophila melanogaster", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 101, no. 35, 31 August 2004 (2004-08-31), pages 12980 - 12985, XP002441529, ISSN: 0027-8424 *
DHAHBI JOSEPH M ET AL: "Identification of potential caloric restriction mimetics by microarray profiling", PHYSIOLOGICAL GENOMICS, vol. 23, no. 3, November 2005 (2005-11-01), pages 343 - 350, XP002441528, ISSN: 1094-8341 *
INGRAM D K ET AL: "Calorie restriction mimetics: An emerging research field", AGING CELL 2006 UNITED KINGDOM, vol. 5, no. 2, 2006, pages 97 - 108, XP002441530, ISSN: 1474-9718 1474-9726 *
ROTH G S ET AL: "Caloric restriction mimetics: The next phase", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES 2005 UNITED STATES, vol. 1057, 2005, pages 365 - 371, XP002441527, ISSN: 0077-8923 *
SEO D ET AL: "Genomic medicine: bringing biomarkers to clinical medicine", CURRENT OPINION IN CHEMICAL BIOLOGY, CURRENT BIOLOGY LTD, LONDON, GB, vol. 9, no. 4, August 2005 (2005-08-01), pages 381 - 386, XP004986468, ISSN: 1367-5931 *
SOVAK M: "Grape extract, resveratrol, and its analogs: A review", JOURNAL OF MEDICINAL FOOD 2001 UNITED STATES, vol. 4, no. 2, 2001, pages 93 - 105, XP008080990, ISSN: 1096-620X *
VALENZANO ET AL: "Resveratrol Prolongs Lifespan and Retards the Onset of Age-Related Markers in a Short-Lived Vertebrate", CURRENT BIOLOGY, CURRENT SCIENCE,, GB, vol. 16, no. 3, 7 February 2006 (2006-02-07), pages 296 - 300, XP005276165, ISSN: 0960-9822 *

Also Published As

Publication number Publication date
WO2007109102A2 (fr) 2007-09-27

Similar Documents

Publication Publication Date Title
Wilton et al. Microglia and complement mediate early corticostriatal synapse loss and cognitive dysfunction in Huntington’s disease
Smith et al. Cirrhosis: diagnosis and management
Nemzek et al. Humane endpoints in shock research
Lee et al. A novel porcine model of traumatic thoracic spinal cord injury
Bertero et al. A YAP/TAZ-miR-130/301 molecular circuit exerts systems-level control of fibrosis in a network of human diseases and physiologic conditions
Coltman et al. Selective white matter pathology induces a specific impairment in spatial working memory
Salazar et al. Inhibition of calpain prevents muscle weakness and disruption of sarcomere structure during hindlimb suspension
Smith et al. Roadmap for advancing pre-clinical science in traumatic brain injury
WO2003003162A3 (fr) Evaluation de maladies neuropsychiatriques au moyen d'une base de donnees associee a des specimens
Hemshekhar et al. Buprenorphine alters inflammatory and oxidative stress molecular markers in arthritis
Petković et al. Nitric oxide inhibits CXCL12 expression in neuroinflammation
Sundaramurthy et al. A 3-D finite-element minipig model to assess brain biomechanical responses to blast exposure
Kumstel et al. Grading animal distress and side effects of therapies
Talbot et al. Robustness of a multivariate composite score when evaluating distress of animal models for gastrointestinal diseases
Li et al. Association of hypertension and long‐term blood pressure changes with new‐onset diabetes in the elderly: A 10‐year cohort study
De Grado et al. Charcot-Marie-Tooth disease: a review of clinical developments and its management-What’s new in 2025?
WO2007109102A3 (fr) procedes d'intervention et de test d'agents mimetiques de restriction calorique (RC)
Cohen et al. Overlap between dissociation and other psychological characteristics in patients with psychogenic nonepileptic seizures
BRPI0407300A (pt) Usos de um inibidor funcional da proteìna hsgk1 ou da proteìna hsgk3 ou de um regulador negativo da transcrição do gene hsgk1 ou do gene hsgk3, de um ácido nucleico de filamento único ou filamento duplo e de um anticorpo, fármaco, kit para diagnóstico, e, método de triagem para identificar e caracterizar substâncias terapeuticamente ativas
Sun et al. Prognostic value of serum Mrp 8/14 in sepsis-induced acute respiratory distress syndrome patients: a retrospective cohort study
GB0724393D0 (en) Use of FKBPL gene to identify a cause of infertility
De Santis et al. Non-invasive MRI windows to neuroinflammation
EA201490548A1 (ru) Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости
Krueger et al. Evaluation of score parameters for severity assessment of surgery and liver cirrhosis in rats
Lauren et al. Disease spread through contiguity and axonal tracts in primary lateral sclerosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07753210

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07753210

Country of ref document: EP

Kind code of ref document: A2